Cormorant Asset Management as of Sept. 30, 2015
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 87 positions in its portfolio as reported in the September 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Heron Therapeutics (HRTX) | 6.6 | $41M | 1.7M | 24.40 | |
| Alkermes (ALKS) | 6.6 | $41M | 700k | 58.67 | |
| Neurocrine Biosciences (NBIX) | 4.6 | $29M | 719k | 39.79 | |
| Dyax | 4.3 | $27M | 1.4M | 19.09 | |
| Ardelyx (ARDX) | 4.1 | $26M | 1.5M | 17.28 | |
| Alder Biopharmaceuticals | 4.0 | $25M | 758k | 32.76 | |
| Eagle Pharmaceuticals (EGRX) | 3.5 | $22M | 300k | 74.03 | |
| Omeros Corporation (OMER) | 3.4 | $22M | 2.0M | 10.96 | |
| Portola Pharmaceuticals | 3.4 | $21M | 500k | 42.62 | |
| Sorrento Therapeutics (SRNEQ) | 2.8 | $18M | 2.1M | 8.39 | |
| Quotient | 2.3 | $15M | 1.1M | 13.00 | |
| Dynavax Technologies (DVAX) | 2.2 | $14M | 575k | 24.54 | |
| Dex (DXCM) | 2.1 | $13M | 153k | 85.86 | |
| BioCryst Pharmaceuticals (BCRX) | 2.0 | $12M | 1.1M | 11.40 | |
| Nevro (NVRO) | 2.0 | $12M | 265k | 46.39 | |
| Tesaro | 1.9 | $12M | 291k | 40.10 | |
| Coherus Biosciences (CHRS) | 1.8 | $11M | 569k | 20.04 | |
| Novavax | 1.8 | $11M | 1.6M | 7.07 | |
| Alnylam Pharmaceuticals (ALNY) | 1.8 | $11M | 140k | 80.36 | |
| Ultragenyx Pharmaceutical (RARE) | 1.7 | $11M | 110k | 96.31 | |
| Sage Therapeutics (SAGE) | 1.6 | $10M | 240k | 42.32 | |
| China Biologic Products | 1.6 | $10M | 112k | 89.82 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 1.6 | $9.9M | 450k | 22.11 | |
| Recro Pharma (SCTL) | 1.5 | $9.4M | 780k | 12.03 | |
| Pfenex | 1.5 | $9.4M | 625k | 15.01 | |
| Mirati Therapeutics | 1.4 | $8.8M | 255k | 34.42 | |
| Rockwell Medical Technologies | 1.4 | $8.5M | 1.1M | 7.71 | |
| Advaxis | 1.3 | $8.2M | 800k | 10.23 | |
| Lipocine | 1.3 | $7.9M | 667k | 11.83 | |
| Forward Pharma A/s | 1.3 | $7.9M | 335k | 23.56 | |
| Seres Therapeutics (MCRB) | 1.2 | $7.4M | 250k | 29.64 | |
| Agenus (AGEN) | 1.1 | $7.2M | 1.6M | 4.60 | |
| Minerva Neurosciences | 1.0 | $6.0M | 1.1M | 5.25 | |
| Regulus Therapeutics | 0.9 | $5.9M | 897k | 6.54 | |
| Curis | 0.8 | $5.3M | 2.6M | 2.02 | |
| Zynerba Pharmaceuticals | 0.8 | $5.1M | 357k | 14.31 | |
| Acceleron Pharma | 0.8 | $5.0M | 200k | 24.90 | |
| Atara Biotherapeutics (ATRA) | 0.8 | $4.7M | 150k | 31.44 | |
| Aptose Biosciences | 0.8 | $4.7M | 1.1M | 4.36 | |
| Intec Pharma | 0.7 | $4.5M | 800k | 5.60 | |
| Nektar Therapeutics (NKTR) | 0.7 | $4.4M | 398k | 10.96 | |
| Epirus Biopharmaceuticals In (EPRSQ) | 0.6 | $4.0M | 897k | 4.42 | |
| Dermira | 0.6 | $4.0M | 170k | 23.34 | |
| Array BioPharma | 0.6 | $3.9M | 850k | 4.56 | |
| Kite Pharma | 0.6 | $3.8M | 69k | 55.68 | |
| Epizyme | 0.6 | $3.4M | 266k | 12.86 | |
| Regenxbio Inc equity us cm (RGNX) | 0.6 | $3.5M | 157k | 22.03 | |
| Karyopharm Therapeutics (KPTI) | 0.5 | $3.2M | 301k | 10.53 | |
| Celyad Sa | 0.5 | $3.1M | 75k | 41.85 | |
| Lion Biotechnologies | 0.5 | $2.9M | 500k | 5.76 | |
| Genvec | 0.4 | $2.7M | 1.2M | 2.31 | |
| Tetralogic Pharmaceuticals c note 8.000% 6/1 | 0.4 | $2.7M | 5.0M | 0.53 | |
| Acelrx Pharmaceuticals | 0.4 | $2.6M | 850k | 3.05 | |
| Glycomimetics (GLYC) | 0.4 | $2.6M | 459k | 5.60 | |
| Immune Design | 0.4 | $2.3M | 189k | 12.20 | |
| Amicus Therapeutics (FOLD) | 0.3 | $2.1M | 150k | 13.99 | |
| Ovascience | 0.3 | $2.1M | 252k | 8.49 | |
| Aquinox Pharmaceuticals | 0.3 | $2.1M | 150k | 14.07 | |
| Blueprint Medicines (BPMC) | 0.3 | $2.1M | 100k | 21.34 | |
| Sangamo Biosciences (SGMO) | 0.3 | $2.0M | 361k | 5.64 | |
| Dicerna Pharmaceuticals | 0.3 | $2.0M | 245k | 8.21 | |
| Cerulean Pharma | 0.3 | $2.0M | 551k | 3.66 | |
| AVEO Pharmaceuticals | 0.3 | $1.9M | 1.6M | 1.21 | |
| Versartis | 0.3 | $2.0M | 170k | 11.53 | |
| Kindred Biosciences | 0.3 | $1.7M | 329k | 5.20 | |
| Quotient Ltd *w exp 10/30/201 | 0.3 | $1.6M | 500k | 3.26 | |
| Htg Molecular Diagnostics | 0.2 | $1.5M | 201k | 7.62 | |
| Provectus Biopharmaceuticals I (PVCT) | 0.2 | $1.3M | 2.2M | 0.58 | |
| Agile Therapeutics | 0.2 | $1.2M | 182k | 6.74 | |
| Cellectar Biosciences | 0.2 | $1.0M | 530k | 1.97 | |
| Contrafect | 0.2 | $1.0M | 234k | 4.45 | |
| Ascendis Pharma A S (ASND) | 0.2 | $1.1M | 62k | 17.71 | |
| Pronai Therapeutics | 0.2 | $1.1M | 53k | 20.53 | |
| Neos Therapeutics | 0.2 | $1.1M | 50k | 21.02 | |
| Akebia Therapeutics (AKBA) | 0.1 | $969k | 100k | 9.66 | |
| Scynexis | 0.1 | $723k | 99k | 7.28 | |
| Galectin Therapeutics (GALT) | 0.1 | $670k | 286k | 2.34 | |
| Provectus Biopharmaceuticals *w exp 06/24/202 | 0.1 | $682k | 2.2M | 0.31 | |
| Akari Therapeutics | 0.1 | $687k | 29k | 23.98 | |
| Nanostring Technologies (NSTGQ) | 0.1 | $640k | 40k | 16.00 | |
| Veracyte (VCYT) | 0.1 | $647k | 138k | 4.69 | |
| Biotie Therapies Corp. ads | 0.1 | $655k | 50k | 13.10 | |
| Cellectar Biosciences Inc *w exp 08/19/201 | 0.1 | $451k | 530k | 0.85 | |
| Cellectis S A (CLLS) | 0.1 | $298k | 11k | 26.37 | |
| Adaptimmune Therapeutics (ADAP) | 0.1 | $299k | 25k | 11.96 | |
| Applied Genetic Technol Corp C | 0.0 | $225k | 17k | 13.15 | |
| Heron Therapeutics | 0.0 | $100k | 5.0k | 20.00 |
